Chat with us, powered by LiveChat

Aabama Defense Lawyer, Board of Pharmacy, Pharmacy Defense Attorney, KLF

FDA Approves Vancomycin Hydrochloride Oral Liquid Therapy for CDAD – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889

Officials with the FDA have approved vancomycin hydrochloride (Firvanq, CutisPharma) for oral solution for the treatment of Clostridium difficile associated diarrhea (CDAD) and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, according to a press release.

The vancomycin hydrochloride oral solution will be available in 25 mg/mL and 50 mg/mL strengths in 150 mL and 300 mL sizes. The availability of an oral liquid therapy is expected to improve patient access and reduce pharmacist burden of having to compound liquid formulations.

“As a practicing infectious disease physician treating many patients with CDAD, having an FDA-approved vancomycin oral liquid formulation that is affordable and accessible to my patients is very beneficial,” Stuart Johnson, MD, Loyola University Medical Center, said in the press release.

CutisPharma anticipates Firvanq to be launched on April 2, 2018. The product will replace CutisPharma’s FIRST Vancomycin Unit-of-Use Compounding Kit.